--- title: "Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings" type: "News" locale: "en" url: "https://longbridge.com/en/news/290504387.md" description: "Iovance Biotherapeutics (IOVA) filed new shelf registrations, providing flexibility for future capital raising and employee incentives. Despite a recent stock price dip to $3.91, the company shows strong long-term momentum with over 50% year-to-date returns. Analysis suggests IOVA is undervalued by approximately 53.2%, with a fair value estimate of $8.35, driven by advancing late-stage TIL therapies. However, risks remain due to reliance on Amtagvi and regulatory uncertainties." datetime: "2026-06-23T03:01:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290504387.md) - [en](https://longbridge.com/en/news/290504387.md) - [zh-HK](https://longbridge.com/zh-HK/news/290504387.md) --- # Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings ## What Iovance’s New Shelf Registrations Mean For Investors Iovance Biotherapeutics (IOVA) recently filed multiple shelf registrations, including an omnibus mixed shelf and smaller ESOP related common stock offerings. These filings give the company broad flexibility to issue new securities when it chooses. These filings sit alongside a recent shareholder approved increase in authorized common shares. Together, they shape how Iovance Biotherapeutics might approach future capital raising, employee incentives, and potential dilution for existing shareholders. See our latest analysis for Iovance Biotherapeutics. Recent filings around new shelf registrations and inducement stock options come at a time when Iovance Biotherapeutics has seen its short term share price soften but longer term momentum build, with a 55.16% year to date share price return and a 111.35% 1 year total shareholder return, set against weaker 3 year and 5 year total shareholder returns. If you are comparing Iovance Biotherapeutics with other cancer focused opportunities, this is a good moment to scan a broader set of healthcare related AI companies through our curated 38 healthcare AI stocks With Iovance Biotherapeutics trading at $3.91 and at a large discount to the average analyst price target of $8.80 despite strong 1 year returns, investors may wonder whether this represents a genuine opportunity or whether the market is already pricing in future growth. ## Most Popular Narrative: 53.2% Undervalued The most followed narrative currently places Iovance Biotherapeutics at a fair value of $8.35 per share versus the last close of $3.91, which frames a sizeable valuation gap for investors to interpret. > _Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook._ _Read the complete narrative._ Want to see how this story turns into numbers? Revenue expansion, margin repair, and a rich future earnings multiple all sit at the core of this valuation. Curious which assumptions have the biggest impact on that fair value and how sensitive they are to setbacks or outperformance? The full narrative lays out those moving parts in detail. **Result: Fair Value of $8.35 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this Iovance Biotherapeutics narrative still faces real pressure from its heavy dependence on Amtagvi, as well as ongoing regulatory and pricing uncertainties around high cost cell therapies. Find out about the key risks to this Iovance Biotherapeutics narrative. ## Next Steps Feeling torn between the upside potential and the concerns raised around Iovance Biotherapeutics? Take a closer look at the data, weigh both sides, and check the 3 key rewards and 2 important warning signs ## Looking for more investment ideas beyond Iovance Biotherapeutics? If you are weighing Iovance Biotherapeutics against other possibilities, it can help to widen your search and compare several different types of opportunities side by side. - Target potential upside by scanning screener containing 19 high quality undiscovered gems that combine solid fundamentals with under-the-radar profiles other investors may be overlooking. - Prioritise resilience by filtering for 66 resilient stocks with low risk scores that focus on companies with lower risk scores across balance sheet, earnings quality, and volatility. - Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (48 results) to see which companies pair financial stability with consistent fundamentals. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md) ## Related News & Research - [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md) - [Iovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors](https://longbridge.com/en/news/295105932.md) - [Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?](https://longbridge.com/en/news/294783383.md) - [Clene says ALS biomarker analyses show CNM-Au8 survival benefit in NfL responders](https://longbridge.com/en/news/295404884.md) - [Iovance Biotherapeutics (IOVA) Stock Valuation After Australia’s Conditional Approval Of Amtagvi](https://longbridge.com/en/news/289712978.md)